Table 1 Baseline clinical characteristics of all the participants analyzed
Characteristic | n | Median (Q1-Q3) or no.(%) |
|---|---|---|
Demographics | ||
Age | 486 | 75(69,80) |
Sex, male | 486 | 231(47.5%) |
Drink | 486 | 46(9.5%) |
Smoke | 486 | 142(29.2%) |
BMI | 482 | 23.9(20.8,28.7) |
Weight loss | 486 | 3.0(0,6.0) |
LOS | 486 | 20(14,28) |
Assessment of CGA | ||
GS | 428 | 24(18.9,31.8) |
WS | 409 | 0.9(0.7,1.1) |
TUG | 334 | 10.9(8.8,13.0) |
5TSTS | 324 | 11.3(9.0,14.0) |
SPPB | 486 | 10(5.0,12.0) |
ADL | 486 | 6(4,6) |
IADL | 486 | 8(5.0,8.0) |
ADL-admitted | 486 | 90(70,95) |
ADL-discharge | 486 | 95(75,100) |
Anxiety | 446 | 75(15.4%) |
Depression | 446 | 116(23.9%) |
Cognition | 444 | 102(21%) |
MMSE | 444 | 27(25,29) |
Frailty-FRAIL | 486 | 207(42.6%) |
Nutrition-MNA-SF | 486 | 11(9,14) |
Malnutrition | 486 | 250(51.4%) |
Impaired vision | 486 | 45(9.3%) |
Impaired hearing | 486 | 56(11.5%) |
Sleep disturbance | 486 | 216(44.4%) |
Constipation | 486 | 65(13.4%) |
Fall | 486 | 115(23.7%) |
Number of drugs | 486 | 6(4,8) |
Polypharmacy | 486 | 310(63.8%) |
Lab values | ||
NLR | 486 | 2.2(1.5,3.4) |
PLT | 486 | 200(162,247) |
Hemoglobin | 486 | 123(110,136) |
Creatinine | 484 | 73(63,90) |
Albumin | 486 | 39(36,41) |
hsCRP | 436 | 2.3(0.8,7.5) |
ESR | 375 | 14(7,30) |
TC | 464 | 3.9(3.3,4.6) |
TG | 464 | 1.1(0.8,1.6) |
HDL-C | 464 | 1.0(0.9,1.3) |
LDL-C | 464 | 2.3(1.8,2.7) |
Clinical condition | ||
CKD | 486 | 87(17.9%) |
HF | 486 | 88(18.1%) |
Dementia | 486 | 36(7.4%) |
Diabetes | 486 | 207(42.6%) |
Cancer | 486 | 100(20.6%) |
Stroke | 486 | 77(15.8%) |
CLD | 486 | 86(17.7%) |
MI | 486 | 23(4.7%) |
Hypertention | 486 | 320(65.8%) |
CCI | 486 | 3(1,4) |